Literature DB >> 24037788

Integration of cancer genomics with treatment selection: from the genome to predictive biomarkers.

Thomas J Ow1, Vlad C Sandulache, Heath D Skinner, Jeffrey N Myers.   

Abstract

The field of cancer genomics is rapidly advancing as new technology provides detailed genetic and epigenetic profiling of human cancers. The amount of new data available describing the genetic make-up of tumors is paralleled by rapid advances in drug discovery and molecular therapy currently under investigation to treat these diseases. This review summarizes the challenges and approaches associated with the integration of genomic data into the development of new biomarkers in the management of cancer.
Copyright © 2013 American Cancer Society.

Entities:  

Keywords:  biologic markers; clinical trials as topic; computational biology; genomics; molecular targeted therapy; neoplasms; systems biology; therapeutics

Mesh：

Substances：

Year:  2013        PMID： 24037788      PMCID： PMC3930628          DOI： 10.1002/cncr.28304

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  97 in total

1.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Authors:  H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

Review 2.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

3.  A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase.

Authors:  F Sanger; A R Coulson
Journal:  J Mol Biol       Date:  1975-05-25       Impact factor: 5.469

4.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

5.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

6.  Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation.

Authors:  Robert Lucito; John Healy; Joan Alexander; Andrew Reiner; Diane Esposito; Maoyen Chi; Linda Rodgers; Amy Brady; Jonathan Sebat; Jennifer Troge; Joseph A West; Seth Rostan; Ken C Q Nguyen; Scott Powers; Kenneth Q Ye; Adam Olshen; Ennapadam Venkatraman; Larry Norton; Michael Wigler
Journal:  Genome Res       Date:  2003-09-15       Impact factor: 9.043

7.  Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression.

Authors:  Christine H Chung; Joel S Parker; Gamze Karaca; Junyuan Wu; William K Funkhouser; Dominic Moore; Dale Butterfoss; Dong Xiang; Adam Zanation; Xiaoying Yin; William W Shockley; Mark C Weissler; Lynn G Dressler; Carol G Shores; Wendell G Yarbrough; Charles M Perou
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

8.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Authors:  David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205
View more
  6 in total

1.  Hsa-microRNA-181a is a regulator of a number of cancer genes and a biomarker for endometrial carcinoma in patients: a bioinformatic and clinical study and the therapeutic implication.

Authors:  Shuming He; Shumei Zeng; Zhi-Wei Zhou; Zhi-Xu He; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2015-02-18       Impact factor: 4.162

2.  Comparative Effectiveness of Biomarkers to Target Cancer Treatment: Modeling Implications for Survival and Costs.

Authors:  Jeanette K Birnbaum; Foluso O Ademuyiwa; Josh J Carlson; Leslie Mallinger; Mark W Mason; Ruth Etzioni
Journal:  Med Decis Making       Date:  2015-08-24       Impact factor: 2.583

3.  Reporting tumor molecular heterogeneity in histopathological diagnosis.

Authors:  Andrea Mafficini; Eliana Amato; Matteo Fassan; Michele Simbolo; Davide Antonello; Caterina Vicentini; Maria Scardoni; Samantha Bersani; Marisa Gottardi; Borislav Rusev; Giorgio Malpeli; Vincenzo Corbo; Stefano Barbi; Katarzyna O Sikora; Rita T Lawlor; Giampaolo Tortora; Aldo Scarpa
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

4.  Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility.

Authors:  Bin Li; Steven A Eschrich; Anders Berglund; Melissa Mitchell; David Fenstermacher; Hadi Danaee; Hongyue Dai; Daniel Sullivan; William L Trepicchio; William S Dalton
Journal:  JMIR Res Protoc       Date:  2017-03-20

Review 5.  New insights into the interplay between long non-coding RNAs and RNA-binding proteins in cancer.

Authors:  Zi-Ting Yao; Yan-Ming Yang; Miao-Miao Sun; Yan He; Long Liao; Kui-Sheng Chen; Bin Li
Journal:  Cancer Commun (Lond)       Date:  2022-01-12

6.  Identification of novel prognosis-related genes associated with cancer using integrative network analysis.

Authors:  YongKiat Wee; Yining Liu; Jiachun Lu; Xiaoyan Li; Min Zhao
Journal:  Sci Rep       Date:  2018-02-19       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.